Abstract
Nivolumab (Nivo) effectively treats malignant pleural mesothelioma (MPM) and serves as second-line therapy after the development of resistance to cisplatin-plus-pemetrexed (CDDP+PEM) chemotherapy. However, the biomarkers of MPM are not fully understood. p16 is a tumor suppressor gene involved in cell cycle regulation. Some MPM patients exhibit homozygous deletions of p16, associated with poor prognosis. MTAP immunohistochemistry (IHC) has been reported to serve as a surrogate for p16 evaluation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
